Testing obeticholic acid for fatty liver in chronic hepatitis B patients
Part of Digestive system, Infections clinical trials.
This trial studies whether adding obeticholic acid to standard treatment can improve fatty liver and liver blood flow in people with chronic hepatitis B. It uses a special ultrasound (FibroScan) to measure liver fat and stiffness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have chronic hepatitis B (HBV) and are on treatment.
- Your liver fat level (CAP score) is higher than 238 dB/m, as measured by FibroScan.
- You do not have other active viral hepatitis infections (like hepatitis C).
- You do not have liver cancer (hepatocellular carcinoma) or a blood clot in the portal vein.
- You do not have other causes of fatty liver, such as heavy alcohol use or certain medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ACT500 in people who have both fatty liver disease and chronic hepatitis B infection. The goal is to understand how safe the drug is and how well it works to improve liver health.
This study follows adults with chronic hepatitis B who also have fatty liver and tests an exercise approach to see how it affects liver health. You may be followed over time and helped with an exercise plan if you qualify.
This trial tests a medicine called peg-interferon for people who have both chronic hepatitis B and fatty liver. It aims to see if the treatment is safe and effective in helping your body fight the hepatitis B virus.
This trial tests a new medication for people with fatty liver disease. It will see if the drug can reduce liver fat and improve liver health over several doses.
This study tests whether adding a pegylated interferon (a medicine that boosts your immune system) to your current hepatitis B treatment can help lower your hepatitis B virus levels even more. It is for people with chronic hepatitis B who have not had interferon recently and do not have fatty liver disease.
This study tests whether a specially designed gut bacteria treatment can help people with fatty liver disease and related health issues like high blood sugar, high cholesterol, or high blood pressure. It aims to see if the treatment is safe and improves liver health.
Hear when a new Steatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.